V-5 Immunitor: Completed Phase IIb enrollment

Immunitor completed enrollment of 120 patients in the double-blind, placebo-controlled, Ukrainian Phase IIb Study imm01 trial to evaluate once-daily oral V5 plus standard of care (SOC) consisting of e...